Good MorningThe S&P 500 pulled back on Thursday following better-than-expected results from Walmart. The world's largest retailer reported top and bottom-line outperformance driven by strength in all categories. The bad news is that guidance is weak and forecasts growth to slow. The result is a 6% decline in WMT's share price and market top that may remain in place until later this year.
Next week could be a volatile one for the S&P 500. The market faces earnings reports from numerous retailers and a critical economic release due Friday. The January read of the PCE price index is due and likely to confirm sticky inflation. The market could enter a correction in this scenario due to the impact on the FOMC rate reduction timeline. The FOMC is expected to lower interest rates, but the timing is uncertain and may not be until 2026. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Consumer Staples | |
One of the most important things investors need to be aware of in the market is economic data, especially when the S&P 500 trades near or at its all-time highs, such as today. This is because the data will show investors what the charts won’t and that is whether the underlying economy ca... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Finance | |
Bridgewater Associates, founded by famed investor Ray Dalio, loaded up on shares of some big-name stocks in Q4. Bridgewater Associates recently released its Form 13F. Institutional investment managers with more than $100 million in discretionary control over 13F Securities must file this document.... Read the Full Story |
|
Consumer Staples | |
Walmart's (NYSE: WMT) February price correction is a buying signal for long-term investors. The drop is due to slowing growth and tariff fears but does little to alter the long-term outlook for earnings, cash flow, equity gains, and capital return. While slower growth and tariffs are headwinds f... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Consumer Discretionary | |
Tesla Inc. (NASDAQ: TSLA) has had a wild ride over the past few months. In the weeks following Trump’s election victory, the stock soared 130%, reaching an all-time high in December before momentum stalled. Since then, shares have fallen more than 25%, with investors taking profits and shi... Read the Full Story |
|
Technology | |
High-profile stock market stories tend to carry a stigma for investors in the sense that few know whether it’s best to trade these names or just hold them for the long haul. Today, the largest share of attention and capital is centered around the technology sector in the United States, par... Read the Full Story |
|
From Our Partners | | SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors.
Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | | Read Tilson's free analysis and find out what to do with your money |
|
Healthcare | |
Health insurance giant Humana Inc. (NYSE: HUM) stock initially rose in reaction to its fourth quarter of 2024 earnings report despite posting losses.
The medical sector giant was one of the first carriers to sound the alarm of rising inpatient utilization costs, notably with its Medicare Advant... Read the Full Story |
|
Technology | |
Three mega-cap names recently announced billions in share repurchase authorizations. Mega-cap generally refers to stock with market capitalizations of $200 billion or more. Below, I’ll detail exactly how large the buyback authorizations these huge firms have approved are. I’ll also inc... Read the Full Story |
|
Consumer Discretionary | |
However, retail and wholesale beauty stocks have been in a steady decline, with losses accelerating in 2025. Once a Wall Street favorite, Ulta Beauty Inc. (NASDAQ: ULTA) ended 2024 down 11.24% and is currently down 16.05% YTD. Coty Inc. (NYSE: COTY) fared worse, closing 2024 with a 43.96% loss and... Read the Full Story |
|
Consumer Discretionary | |
Most investors fall into what’s called “Indicator purgatory,” where they rely heavily on indicators and chart patterns to tell them where to start buying and selling in the market. However, there comes a point in the economic cycle, such as today, when those strategies become too... Read the Full Story |
|
Industrials | |
Fastenal Inc. (NASDAQ: FAST) is a leading supplier of construction and industrial supplies, including fasteners, bolts, screws, studs, washers, as well as safety supplies and tools for maintenance repair and operations (MRO) products. Muted industrial manufacturing and construction activity amid... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. | Should I Buy Merck & Co., Inc. Stock? MRK Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Merck & Co., Inc. was last updated on Wednesday, October 14, 2026 at 6:28 PM.
Merck & Co., Inc. Bull Case -
Merck is set to present first-time Phase 3 results from three pivotal oncology trials at the upcoming ESMO 2026 conference, which could significantly boost investor confidence in the company's pipeline and its ability to generate growth beyond its flagship Keytruda drug.
-
The stock is currently trading at $147.47, reflecting a strong upward momentum with a 3.6% jump in recent trading, which suggests positive market sentiment ahead of the company's third-quarter earnings report expected in the coming weeks.
-
Merck offers a dividend yield of 2.34%, providing a steady income stream for investors, with the company recently declaring a quarterly dividend of $0.85 per share that was paid on October 7th.
-
Analyst sentiment remains supportive, with a consensus rating of "Moderate Buy" and a consensus price target of $151.92, indicating that many experts believe the stock still has room to grow from its current level.
-
Keytruda continues to drive top-line growth, with sales expansion and new indications expected to support revenue, while the company's partnership with Moderna on a breakthrough cancer vaccine is expected to become faster to manufacture over time.
Merck & Co., Inc. Bear Case -
Merck faces significant competitive risks, including the looming threat of biosimilar competition for Keytruda in 2028-2029, which could erode the drug's market share and revenue contribution in the future.
-
The company's valuation is elevated, with a P/E ratio of 117.97, which may limit upside potential if earnings growth does not meet high expectations, and the firm has reported a negative operating margin in recent periods.
-
Jefferies has cut its peak-sales forecast for Merck's experimental eye drug remigromig by 60% following efficacy and safety concerns in recent trials, highlighting the risks associated with the company's pipeline development.
-
Erste Group Bank has reduced its FY2026 and FY2027 earnings per share estimates for Merck, reflecting a more cautious outlook on the company's near-term profitability and financial performance.
-
Insider selling activity has been notable, with executives such as EVP Chirfi Guindo and EVP David Williams selling significant portions of their holdings in August 2026, which may signal a lack of confidence in the stock's short-term prospects.
| | View Today's Stock Pick |
|
